A new combination therapy which
destroys some of the most deadly cancer tumors has been found to be
even more effective than was first thought.
Early trials on the drugs for skin cancer had already been hailed as showing “spectacular” results, with a significant reduction in more than half of tumors.
New findings show that more 60 per cent of patients, who could expect
to live just nine months on standard treatment, were still alive two
years later.
Also, in more than one in five cases, tumors had been destroyed.
A total of 142 patients were randomly allocated either to receive two drugs, Nivolumab and Ipilimumab, or Ipilimumab alone.
The therapies, consisting of lab-made antibodies, are designed to harness the body’s immune system, to fight cancer.
Findings from a Phase II US-led trial testing the effectiveness of
the drug combination were presented at the annual meeting of the
American Association for Cancer Research in New Orleans.
"The overall survival rates observed using the regimen of Nivolumab plus Ipilimumab are very promising and provide further hope for patients and
their families affected by this disease."
No comments:
Post a Comment